This medicine is now known as ofranergene obadenovec.
On 6 June 2012, orphan designation (EU/3/12/1002) was granted by the European Commission to Gregory Fryer Associates Ltd, United Kingdom, for adenovirus-associated vector containing human Fas-c gene for the treatment of glioma.
In December 2015, Gregory Fryer Associates Ltd changed name to Envigo Pharma Consulting Ltd.
The sponsorship was transferred to Envigo CRS S.A., Spain, in April 2019.
Adenovirus-associated vector containing human Fas-c gene (ofranergene obadenovec)
|Disease / condition||
Treatment of glioma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;